- 2009. The long-acting
injectable form of paliperidone,
marketed as
Invega Sustenna in the US, and
Xeplion in the EU, was
approved by the FDA in July 2009...
-
decanoate Meclopin Typical ? ? ? ? ? 8.5–8.7
Paliperidone palmitate Invega Sustenna Atypical Watera 39–819 mg/4–12 w****s 13–33 days 25–139 days ? 8.1–10.1...
- Janssen-Cilag/Johnson &
Johnson Paliperidone palmitate Benzisoxazole Atypical Invega Sustenna/Xeplion 2009 Janssen-Cilag/Johnson &
Johnson Penfluridol Diphenylbutylpiperidine...
-
decanoate Meclopin Typical ? ? ? ? ? 8.5–8.7
Paliperidone palmitate Invega Sustenna Atypical Watera 39–819 mg/4–12 w****s 13–33 days 25–139 days ? 8.1–10.1...
- for
schizophrenia and
bipolar I disorder,
paliperidone palmitate (Invega
Sustenna,
Invega Trinza and
Invega Hafyerain in the U.S., Xeplion,
Trevicta and...
-
Melneurin Olanzapine Zyprexa,
Zyprexa Relprevv Paliperidone Invega,
Invega Sustenna Quetiapine Seroquel Risperidone Risperdal,
Risperdal Consta Ziprasidone...
-
decanoate Meclopin Typical ? ? ? ? ? 8.5–8.7
Paliperidone palmitate Invega Sustenna Atypical Watera 39–819 mg/4–12 w****s 13–33 days 25–139 days ? 8.1–10.1...
-
decanoate Meclopin Typical ? ? ? ? ? 8.5–8.7
Paliperidone palmitate Invega Sustenna Atypical Watera 39–819 mg/4–12 w****s 13–33 days 25–139 days ? 8.1–10.1...
-
decanoate Meclopin Typical ? ? ? ? ? 8.5–8.7
Paliperidone palmitate Invega Sustenna Atypical Watera 39–819 mg/4–12 w****s 13–33 days 25–139 days ? 8.1–10.1...
-
decanoate Meclopin Typical ? ? ? ? ? 8.5–8.7
Paliperidone palmitate Invega Sustenna Atypical Watera 39–819 mg/4–12 w****s 13–33 days 25–139 days ? 8.1–10.1...
